The molecular diagnostics industry is experiencing explosive growth. Innovation and strategic planning is needed to realize the commercial potential from applied genomics. The number of product offerings for molecular profi ling that allow the early detection, prognosis, and treatment of disease is increasing substantially. But the advance of companion diagnostics has been slow to take hold. There are many questions to be answered: how will drug-diagnostic companion products be co-launched? How will each component be valued? How will joint submissions be regulated? Despite the uncertainty, there are incredible opportunities for partnership in this emerging area of personalized medicine. Come prepared to take part in the dialogue and learn from the key players how molecular diagnostics will impact the practice of medicine.
Explore
Membership
